

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/738,413
Filing Date	December 17, 2003
First Named Inventor	Binetti, R.
Art Unit	1635
Examiner Name	Bowman, Amy Hudson
Attorney Docket Number	SC66U-US

Sheet	1	of	4
-------	---	----	---

U. S. PATENT DOCUMENTS

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
IAB/		US- 6,514,747	02-04-2003	Woychik et al.	
		US- 6,518,488	02-11-2003	Agarwal et al.	
		US- 6,531,647	03-11-2003	Baulcombe et al.	
		US- 5,146,846	09-15-1992	Lee et al.	
		US- 5,223,262	06-29-1993	Kim et al.	
		US- 4,820,724	04-11-1989	Nimni	
		US- 4,379,454	04-12-1983	Campbell et al.	
		US- 4,956,171	09-11-1990	Chang	
		US- 5,770,222	06-23-1998	Unger et al.	
		US- 4,224,179	09-23-1980	Schneider	
		US- 4,235,871	11-25-1980	Papahadjopoulos et al	
		US- 5,847,003	12-08-1998	Ptchelintsev et al.	
		US- 6,069,169	05-30-2000	Ptchelintsev et al.	
		US- 5,932,229	08-03-1999	Ptchelintsev et al.	
		US- 5,834,513	11-10-1998	Ptchelintsev et al.	
		US- 6,573,050 B1	06-03-2003	Ben-David et al.	
		US- 2005/0255181	11-17-2005	Lee	
		US- 2006/0062865	03-23-2006	Ilic et al.	
		US- 6,562,321 B2	05-13-2003	Ptchelintsev et al.	

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Amy Bowman/	Date Considered	03/20/2007
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 2 of 4	Application Number	10/738,413
	Filing Date	December 17, 2003
	First Named Inventor	Binetti, R.
	Art Unit	1635
	Examiner Name	Bowman, Amy Hudson
	Attorney Docket Number	SC66U-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		BOONANUNTANASARN et al., Specific gene silencing using small interfering RNAs in fish embryos, 2003, Biochemical and Biophysical Research Communications, 310, page 1089-1095.	
		CAPLEN et al., dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference, 2000, Gene, 252, pages 95-105.	
		ZHANG et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, 5, pages 1-7.	
		HARTMANN et al., Hypopigmentary skin disorders: current treatment options and future directions, 2004, Drugs, 64(1), pages 89-107.	
		POLLARK, Andrew, Method of Turn Off Bad Genes Is Set for Tests on Human Eyes	
		VAN DE Water et al., Intravenously administered siRNA accumulates in the kidney, Am Soc for Pharm and Experimental Therapeutics, 2006.	
		XIE et al., Harnessing in vivo siRNA delivery for drug discovery and therapeutic development, 2006, Drug Discovery Today, Vol 11, No. 1/2, pages 67-73.	
		ZIMMERMANN et al., RNAi-mediated gene silencing in non-human primates, 2006, Nature Publishing Group, Vol 4414, pages 111-114.	
		MORRIS, Therapeutic potential of siRNA-mediated transcriptional gene silencing, April 2006, Therapeutic Applications of RNAi, page 7-13.	
✓		GAUR, RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases, April 2006, Therapeutic Applications of RNAi, page 15-22.	

Examiner Signature	/Amy Bowman/	Date Considered	03/20/2007
---------------------------	--------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/738,413
Filing Date	December 17, 2003
First Named Inventor	Binetti, R.
Art Unit	1635
Examiner Name	Bowman, Amy Hudson
Attorney Docket Number	SC66U-US

Sheet

3

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		ROSSI, RNAi as a treatment for HIV-1 infection, April 2006, Therapeutic Applications fo RNAi, pages 25-29.	
		RONDINONE, Therapeutic potential of RNAi in metabolic diseases, April 2006, Therapeutic Applications fo RNAi, pages 31-36.	
		BROWN et al., Toward silencing the burden of malaria: progress and prospects for RNAi-based approaches, April 2006, Therapeutic Applications fo RNAi, pages 38-44.	
		MARQUES et al., Activation of the mammalian immune system by siRNAs, 2005, Nature Biotechnology, Vol 23, No. 11, pages 1399-1405.	
		PUSHPARAJ et al., Short interfering RNA (siRNA) as a novel therapeutic, 2006, Clinical and Experimental Pharm and Physiology ,33, p. 504-510.	
		DYKXHOORN et al., Running Interference: Prospects and Obstacles to Using Small Interfering RNAs as Small Molecule Drugs, 2006, Annu. Rev. Biomed. Eng., 8:15.1-15.26.	
		BRUMMELKAMP et al., A System for Stable Expression of Short Interfering RNAs in Mammalian Cells, 2002, Science, 296: 550-553.	
		ELBASHIR et al., Effective expression of small interfering RNA in human cells, 2001, Nature, 411: 494-498.	
		PAUL et. al., Effective expression of small interfering RNA in human cells, 2002, Nature Biotech., 20:505-508.	
↓		HANNON, G., RNA interference, 2002, Nature, 418: 244-251.	

Examiner Signature	/Amy Bowman/	Date Considered	03/20/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 4 of 4	Application Number	10/738,413
	Filing Date	December 17, 2003
	First Named Inventor	Binetti, R.
	Art Unit	1635
	Examiner Name	Bowman, Amy Hudson
	Attorney Docket Number	SC66U-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		CAPLEN, et al., Specific inhibition of gene expression by samll double-stranded RNA in invertebrate and vertebrate systems, 2001, Proc Natl Acad Sci USA, 98:9742-9747.	
		ELBASHIR, et al., Functional anataomy of siRNAsfor mediating effecient RNAi in Drosophila melanogaster embryo lysate, 2001, European Molecular Bio Org Journal, 20:6877-88.	
		JARVIS et al., siRNA-Mediated Gme Silencing in Mamalian Cells, 2002, Ambion, Inc., poster published on the world wide web at ambion.com/techlib/posters/RNAi_0302.html.	
		ROZEMA, D. and Lewis, D., siRna delivery technologies for mammalian systems, 2003, Targets, 2: 253-260.	
		DAVIS S.S. and Walker I.M., Multiple Emulsions as Targetable Delivery Systems, 1987, Methods in Enzymology, 149:51-64.	
		MAYHEW E. et al., High-Pressure Continuous-Flow System for Drug Entrapment in Liposomes, 1987, Methods in Enzymology, 149:64-77.	
		SHAFFER-KORTING M. et al., Liposome preparations: A step forward intopical drug therapy for skin disease?, 1989, J. Am. Acad. Dermatol., 21:1271-1275.	
✓		FLEISCHER et al., The combination of 2% 4-hydroxyanisole (Mequinol)...., J. Am Acad. Dermatol. 2000, vol 42(3): 459-467.	

Examiner Signature	/Amy Bowman/	Date Considered	03/20/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.